1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Research to Address Systemic and Structural Barriers and Facilitators to Improve the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum for People Who Use Substances (R01 Clinical Trials Required) RFA-DA-26-003 is sponsored by National Institute on Drug Abuse (NIDA) - NIH. This funding opportunity supports research to address systemic and structural barriers and facilitators to improve the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum for people who use substances.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar Research to Address Systemic and Structural Barriers and Facilitators to Improve the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum for People Who Use Substances (R01 Clinical Trials Required) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:RFA-DA-26-003 Funding Opportunity Title:Research to Address Systemic and Structural Barriers and Facilitators to Improve the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum for People Who Use Substances (R01 Clinical Trials Required) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Education Expected Number of Awards: Assistance Listings:93.
279 -- Drug Use and Addiction Research Programs 93. 307 -- Minority Health and Health Disparities Research 93. 310 -- Trans-NIH Research Support 93.
313 -- NIH Office of Research on Women's Health Cost Sharing or Matching Requirement:No Last Updated Date:Dec 02, 2024 Original Closing Date for Applications:Mar 12, 2025 Current Closing Date for Applications:Mar 12, 2025 Archive Date:Apr 17, 2025 Estimated Total Program Funding:$ 500,000 Eligible Applicants:Public and State controlled institutions of higher education Independent school districts Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Special district governments Public housing authorities/Indian housing authorities Additional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
## Additional Information Agency Name:National Institutes of Health Description:Pre-exposure prophylaxis, also known as PrEP, is a safe, highly effective medication for preventing transmission of HIV from sex or injection drug use. Despite PrEPs high efficacy and its availability for over a decade, the awareness, uptake, and adherence of PrEP, especially among people who use substances remain suboptimal.
The goal of this concept is to support research to examine and address systemic and structural factors that impede or facilitate the PrEP awareness, uptake, and adherence, among people who use substances. Projects will develop, implement, and evaluate effective strategies that meet the needs of people who use substances to improve the PrEP care continuum. Link to Additional Information:https://grants.
nih. gov/grants/guide/rfa-files/RFA-DA-26-003. html Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: See Section VII.
Agency Contacts within the full opportunity announcement for all other inquires. #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below.
This is being done to protect your privacy. Unsaved changes will be lost.
According to the current listing, eligibility includes: See official notice. Confirm the full requirements in the official notice before applying.
Research to Address Systemic and Structural Barriers and Facilitators to Improve the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum for People Who Use Substances (R01 Clinical Trials Required) RFA-DA-26-003 is funded by National Institute on Drug Abuse (NIDA) - NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 Clinical Trial Optional) is a grant from the National Institute on Drug Abuse (NIDA) at NIH that funds small business concerns to develop science-based technologies add…
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. This SBIR program aims to leverage AI/ML tools to identify pharmacotherapeutic development candidates with lower toxicity and higher efficacy to prevent or treat Substance Use Disorders (SUDs).
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article